|Dr. Mitchell H. Finer||Co-Founder & Director||57.48k||N/A||1959|
|Dr. Mehdi Gasmi||Chief Science & Technology Officer||634.14k||N/A||1967|
|Dr. Amber Salzman||Consultant||442.82k||N/A||1962|
|Ms. Leone D. Patterson||Interim Pres, CEO, Sr. VP & CFO||N/A||N/A||1963|
|Dr. Jennifer Cheng||VP, Gen. Counsel & Corp. Sec.||N/A||N/A||1973|
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of June 1, 2018 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 8; Compensation: 10.